dimanche 20 septembre 2020


Tuesday, March 8th 2016 at 12:30pm UTC

Proceeds will be Used to Advance Company’s Immunotherapy Programs

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– Tizona Therapeutics, Inc., a privately held immunology company
harnessing the power of the immune system to develop treatments for
cancer and autoimmune diseases, today announced the closing of a $43
million Series B financing. Proceeds will be used to advance the
company’s immunotherapy programs. These programs include its lead drug
candidate, an anti-CCR4 monoclonal antibody for the treatment of cancer,
which is expected to enter the clinic in 2017. To date, the company has
raised more than $70 million through its Series A and B financing rounds
to fund its diversified pipeline.

The Series B financing was co-led by Abingworth and Canaan Partners with
investments from Lightstone Ventures and existing Series A investors,
including MPM Capital, Amgen Ventures, Astellas Venture Management and
InterWest Partners. As part of the financing, Shelley Chu, M.D., Ph.D.,
Partner of Abingworth, Nina Kjellson, Partner of Canaan Partners, and
Jean George, General Partner of Lightstone Ventures, have joined
Tizona’s Board of Directors.

“We expect Tizona’s anti-CCR4 antibody to play an important role in
inducing antitumor activity by depleting regulatory T cells (Tregs), a
type of cell crucial to establishing and maintaining an
immunosuppressive tumor microenvironment, ” said Pablo J. Cagnoni, M.D.,
President and Chief Executive Officer of Tizona. “We have an opportunity
to contribute a potentially valuable new addition to the group of novel
immunotherapies that is changing standards of care in cancer treatment.
With support from this investor group, along with our renowned
scientific founders and accomplished team, Tizona is well-positioned to
be a leader in the development of next generation immunotherapies.”

Tizona was co-founded by the world’s preeminent scientific leaders in
translational research and immunotherapy development – Charles G. Drake,
M.D., Ph.D., Professor, Oncology, Immunology and Urology, Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center; Vijay K. Kuchroo, D.V.M.,
Ph.D., Director, Evergrande Center for Immunologic Diseases, Harvard
Medical School; Wayne A. Marasco, M.D., Ph.D., Professor, Cancer
Immunology and Virology, Dana-Farber Cancer Institute, Professor of
Medicine, Harvard Medical School; Drew Pardoll, M.D., Ph.D., Abeloff
Professor of Oncology, Medicine, Pathology and Molecular Biology and
Genetics, Johns Hopkins University, School of Medicine; Dario Vignali,
Ph.D., Vice Chair and Professor of Immunology, Department of Immunology,
University of Pittsburgh School of Medicine, Co-Leader of the Cancer
Immunology Program and Co-Director of the Tumor Microenvironment
Center, University of Pittsburgh Cancer Institute; and Jedd Wolchok,
M.D., Ph.D., Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in
Clinical Investigation, Chief, Melanoma & Immunotherapeutics Service,
Associate Director, Ludwig Center for Cancer Immunotherapy, Professor of
Medicine, Weill Medical College of Cornell University, Memorial
Sloan-Kettering Cancer Center. In addition, Ana Anderson, Ph.D.,
Assistant Professor of Neurology at Harvard Medical School, Core faculty
member of the Evergrande Center for Immunologic Diseases, is a
scientific advisor to the company.

In addition to the anti-CCR4 antibody program, proceeds from the
financing will be used to advance Tizona’s pipeline, including the
company’s IL-35 programs. IL-35 is a recently discovered
immunosuppressive cytokine, predominantly expressed by Tregs. IL-35 is
involved in suppression of anti-tumor immunity through its modulation of
effector T cells, as well as myeloid cells. Blocking IL-35’s activity
may reverse immune suppression in the tumor microenvironment and lead to
a robust and effective anti-tumor immune response. Given IL-35’s potent
suppressive properties, targeting this pathway also holds significant
promise as a potential first-in-class treatment for autoimmune diseases.

About Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company
harnessing the power of the immune system to develop treatments for
cancer and autoimmune disorders. A healthy immune system integrates
information from pro-inflammatory and anti-inflammatory cells that
regulate the immune system’s function. In cancer, tumor cells evade
recognition by controlling cells that suppress the proper function of
the immune system. In autoimmune disease, the immune system attacks
“self” tissues in the body due to insufficient regulation. Tizona’s
therapies are designed to regulate these suppressive cells, thereby
either activating the body’s ability to fight cancer or preventing the
immune system from attacking healthy tissues in autoimmune diseases.
Tizona’s lead drug candidate, an anti-CCR4 monoclonal antibody, is
expected to enter the clinic in 2017. For more information, visit www.tizonatx.com.

Contacts

Tizona Therapeutics, Inc.
Lori Melançon, 1-650-684-7141
Communications
Consultant

Source: Tizona Therapeutics, Inc.

Étiquettes : , , , , , , , , , , ,